Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2005
10/06/2005WO2005092363A1 Preventive/remedy for diabetic complications using oligopeptide
10/06/2005WO2005092359A1 Extract of mucuna species and the use thereof as anti-parkinsons’s disease pharmaceutical
10/06/2005WO2005092348A1 Hgf production accelerator containing heparin-like oligosaccharide
10/06/2005WO2005092320A1 Cytoprotective composition
10/06/2005WO2005063294A8 Inhibitor for the formation of ϝ-secretase complex
10/06/2005WO2005002551A3 Vanilloid receptor (vr) 1 inhibitors for treatment of human immunodeficiency virus (hiv)-mediated pain states
10/06/2005US20050222424 Phenyloxyalkanonic acid derivatives as hppar activators
10/06/2005US20050222418 Novel tyloindicines and related processes, pharmaceutical compositions and methods
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222410 Inhibitors of histone deacetylase
10/06/2005US20050222395 New peptide derivatives
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222275 Use of dmso in the treatment of neurodegenerative diseases caused by prions
10/06/2005US20050222274 Hyperforin halogenated derivatives, the use thereof and formulations containing them
10/06/2005US20050222266 2-indanylamino derivatives for the therapy of chronic pain
10/06/2005US20050222260 (2S)-2-amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
10/06/2005US20050222253 Anti-cancer nitro- and thia-fatty acids
10/06/2005US20050222244 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
10/06/2005US20050222243 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
10/06/2005US20050222237 Inhibitors of glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase; for treatment and prevention of diabetes and Alzheimer's disease
10/06/2005US20050222235 Drugs for improving the prognosis of brain injury and a method of screening the same
10/06/2005US20050222224 p53 Inhibitors and therapeutic use of the same
10/06/2005US20050222220 GSK-3 inhibitors
10/06/2005US20050222216 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
10/06/2005US20050222206 Pyridinoylpiperidines as 5-ht1f agonists
10/06/2005US20050222205 Treatment of pain with ifendropil
10/06/2005US20050222201 such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2)
10/06/2005US20050222196 Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
10/06/2005US20050222194 3-[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-quinolin-2(1H)-ones or 5--[p-(phenoxy, phenylthio, phenylsulfinyl, or phenylsulfonyl)benzyl]-pyrrolo[3,2,1-IJ]quinolin-4(4H)-ones; type E antagonists; analgesics, antipyretics, antiinflammatory agents; side effect reduction
10/06/2005US20050222189 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
10/06/2005US20050222187 A quaternary ammonium salts of 1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine for treating neurodegenerative disorders; chemical synthesis; mixture with other active ingredients; Alzheimer's disease, cerebral edema, brain and nervous system disorders
10/06/2005US20050222181 Compounds in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
10/06/2005US20050222179 Adenosine receptor antagonists and methods of making and using the same
10/06/2005US20050222174 N-{4-[1-(2,6-difluorobenzyl)-3-(4-fluorophenyl)-5-({methy[2-(2-oxo-1-piperidinyl)ethyl]amino}methyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-N'-ethylurea; antagonistic action for gonadotropin-releasing hormone
10/06/2005US20050222172 Active ingredient in treating neurodegenerative disease, Alzheimer's disease caused by abnormal enzyme activity
10/06/2005US20050222164 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
10/06/2005US20050222160 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone, used for inhibiting proliferation of lymphocytes in a host, and for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, arthritis, multiple sclerosis, diabetes
10/06/2005US20050222152 Enzyme inhibitors for disease treatment with Cathepsin s
10/06/2005US20050222147 Process for the preparation of morpholine derivatives and intermediates therefore
10/06/2005US20050222143 Helix mimetics and composition and methods related thereto
10/06/2005US20050222137 Combination of organic compounds
10/06/2005US20050222125 For therapy of depression, anxiety and body weight disorders
10/06/2005US20050222124 Benzenesulfonamide derivatives as antipsychotic agents
10/06/2005US20050222121 Atypical antipsychotic agents having low affinity for the D2 receptor
10/06/2005US20050222114 Use of new etonogestrel esters
10/06/2005US20050222112 Treating psychological dependency (not physical dependancy leading towithdrawal) by administering the agonist (cortisone acetate) and the addictive drug after detoxification of the dependent-patient; highly-dosed and "imprinted"by the mixture eliminates and replaces the "addiction memory"
10/06/2005US20050222104 e.g. 3 beta -Formyloxy-21-acetyloxy-5-pregnen-20-one; modulate immunology response; disease associated to an excess of glucocorticoids; Cushing's syndrome, iatrogenic hypercortisolism or depression
10/06/2005US20050222099 Pregnane steroids for use in the treatment of cns disorders
10/06/2005US20050222097 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
10/06/2005US20050222093 Methods for restoring cognitive function following systemic stress
10/06/2005US20050222091 Use of tyrosine kinase inhibitors for treating cns disorders
10/06/2005US20050222087 Hedgehog antagonists that inhibit the hedgehog pathway in a smoothened gain-of-function cell with an IC50 within a factor of 20, 10, or even a factor of 5, of the IC50 with which they inhibit the hedgehog pathway in a patched-null cell
10/06/2005US20050222078 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
10/06/2005US20050222061 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
10/06/2005US20050222041 oligopeptides capable of stimulating neural cell adhesion molecule (NCAM) signalling and/or interfering with cell adhesion, used for treatment of nervous system disorders
10/06/2005US20050222028 BMP-9 compositions and methods for inducing differentiation of cholinergic neurons
10/06/2005US20050222025 Method of inhibiting fibrosis with a somatostatin agonist
10/06/2005US20050222020 Apoptotically active peptides
10/06/2005US20050222017 Apoptosis promoter and inhibitor interacting with cgi-94, and method of screening the same
10/06/2005US20050221483 Propagating pluripotent stem cells from monocytes; tissue engineering; cell therapy; treating cardiovascular, arteriosclerotic, metabolic and liver disorders; cell expressing albumin protein; cirrhosis of the liver
10/06/2005US20050221479 Process for producing nerve cells
10/06/2005US20050221428 Chimeric neuropeptide Y receptors
10/06/2005US20050221420 Nogo receptor homologues and their use
10/06/2005US20050221391 Reagents and methods for identification of binding agents
10/06/2005US20050221368 Methods for identifying RNA binding compounds
10/06/2005US20050221355 cDNA for human methylenetetrahydrofolate reductase and uses thereof
10/06/2005US20050221344 Interferon-Like molecules and uses thereof
10/06/2005US20050221330 Glial cell line-derived neurotrophic factor (GDNF); nervous system disorders, autonomic nervous system, shingles, asthma, irritable bowel, inflammatory bowel, constipation, headache, arthritis, spinal cord injury, chronic back pain, hypertension, mucositis, diabetes, fibromyalgia, and wound healing
10/06/2005US20050221303 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
10/06/2005US20050221287 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs53 upregulation
10/06/2005US20050220958 Pasteurisation process for microbial cells and microbial oil
10/06/2005US20050220900 Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta
10/06/2005US20050220884 Free-flowing, powdery composition containing alpha-liponic acid (derivates)
10/06/2005US20050220857 Physiologically compatible, phospholipid-containing, stable and hard matrix
10/06/2005US20050220855 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease
10/06/2005US20050220802 Vaccine and method for treatment of motor neurone diseases
10/06/2005US20050220761 stimulating neural progenitor cells by culturing the cells ex vivo with a composition comprising IL6R/IL6 chimera, fused protein, functional derivative, circularly permutated derivative prior to transplantation; used for loss or atrophy of neurons caused by aging or by a neurological disease
10/06/2005US20050220759 Treating multiple sclerosis by orally administering an excipient and a RANTES polypeptide or a macrophage inflammatory protein; preventing autoimmune and inflammatory diseases and bacterial and viral infections
10/06/2005US20050220715 Methods and compositions for improving drug safety
10/06/2005DE20122435U1 Mikronisiertes Zolpidem-Hemitartrat Micronized zolpidem hemitartrate
10/06/2005CA2561696A1 Novel modified galectin 9 proteins and use thereof
10/06/2005CA2561639A1 Novel urea derivatives and their medical use
10/06/2005CA2561117A1 Decoy nucleic acid to synoviolin gene promoter
10/06/2005CA2560905A1 Conjugated psychotropic drugs and uses thereof
10/06/2005CA2560902A1 Treatment of neurological conditions using complement c5a receptor modulators
10/06/2005CA2560869A1 Treatment of neurodegenerative diseases by the use of laptm4b
10/06/2005CA2560741A1 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
10/06/2005CA2560700A1 Tetrahydrocarbazoles and derivatives
10/06/2005CA2560243A1 Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
10/06/2005CA2559266A1 Combinations comprising alpha-2-delta ligands
10/06/2005CA2558889A1 Selected cgrp antagonists, methods for the production thereof and their use as medicaments
10/06/2005CA2558311A1 Novel use of peptide compounds for treating pain in painful diabetic neuropathy
10/06/2005CA2558307A1 Disintegrating tablets comprising licarbazepine
10/06/2005CA2554074A1 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain
10/06/2005CA2554073A1 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
10/06/2005CA2554041A1 Process for the preparation of 3-amino-8-(1-piperazinyl) -2h-1-benzopyran-2-one and salts and hydrates thereof
10/06/2005CA2534445A1 Agent for promoting hgf production comprising heparin-like oligosaccharides
10/05/2005EP1582586A1 Apoptosis-associated protein and use thereof
10/05/2005EP1582521A1 Fused furan compound
10/05/2005EP1582517A1 Blood-brain barrier disruption inhibitors
1 ... 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 ... 1833